Recently, angiotensin-receptor neprilysine-inhibitor (ARNI) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been added to the medical treatment for CHF with impressive effects on both morbidity and mortality [45,46,47]. This evidence concerns the gene SLC5A2 and congestive heart failure.